Moore Kuehn, PLLC Encourages Investors of Ionis Pharmaceuticals, Inc. to Contact Law FirmNewsfile Corp • 01/21/22
Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategyPRNewsWire • 01/19/22
Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trialPRNewsWire • 01/18/22
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMAPRNewsWire • 01/04/22
Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding DisorderBenzinga • 12/07/21
Ionis Pharmaceuticals (IONS) Down 24.5% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/03/21
Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsenPRNewsWire • 11/24/21
Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedemaPRNewsWire • 11/18/21
Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021PRNewsWire • 11/12/21
Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meetingPRNewsWire • 11/07/21
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21